Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Polyoxyethylene (8) Stearate BP EP USP Pharma Grade comes from the reaction between stearic acid, a common fatty acid sourced from both animal and vegetable origins, and ethylene oxide. This reaction creates a non-ionic surfactant that pharmaceutical firms have leaned on for decades. As a material, it works well as an emulsifier, which means it helps ingredients that don’t usually mix—like oil and water—stay together in a stable solution. In my years involved with pharmaceutical and food production, I’ve encountered its utility in many labs, where formulas demand reliability batch after batch. Because its nature steers clear of charged groups, this surfactant brings fewer unwanted reactions, which matters when purity and predictable behavior drive drug formulation decisions. Ningjiang Chemical and other well-known companies list this compound as an approved raw material suited for use in manufacturing sensitive products where international pharmacopoeia standards—BP, EP, USP—must be met.
The backbone structure features a lengthy stearic acid hydrocarbon tail attached to an eight-unit polyoxyethylene chain. This combo forms C40H80O9—a molecular formula showing forty carbons, eighty hydrogens, and nine oxygens. In a structural sense, each ethylene oxide group contributes two carbons and one oxygen. Linking eight of these to the stearate establishes the polyoxyethylene segment, which gives it a strong ability to dissolve in water. By count, the eight polyoxyethylene repeat units per molecule help define specific attributes and make this particular grade different from alternatives with shorter or longer polyoxyethylene chains.
Polyoxyethylene (8) Stearate takes on various physical forms. Most often, it comes as off-white waxy flakes or solid pearls, though some suppliers offer it ground into a fine powder. The substance has a tendency to feel smooth and greasy to the touch, much like many other non-ionic emulsifiers built from fatty acids. At room temperature, it keeps its solid state but will melt and turn into a clear liquid as temperatures rise, usually between 45°C and 55°C. Density hovers around 1.03–1.06 g/cm³ at 20°C, which allows for manageable measurement and mixing, particularly when precise concentrations must go into pharmaceutical batches or food-grade products. Solubility depends on temperature; the surfactant dissolves in both water and alcohol, producing clear to opalescent solutions, while showing poor solubility in oils unless heated. That property has helped many teams process creams, ointments, and liquid medications where a stable emulsion marks the difference between product success and product recall.
In pharmaceutical manufacturing, Polyoxyethylene (8) Stearate stands out mainly as an emulsifier and solubilizer. These two traits shine during production of creams, lotions, and suspensions meant for both topical and oral use. I’ve watched quality control labs trust this ingredient to improve the texture, consistency, and shelf life of sensitive preparations. Suspensions and drops need particles to stay evenly distributed; otherwise, doses become unreliable and unsafe. In oral forms, taste-masking often proves challenging, so this surfactant sometimes smooths out bitterness, making medicine easier for children and the elderly. On the excipient lists approved by top regulatory bodies, Polyoxyethylene (8) Stearate receives regular inclusion thanks to its safety profile, ease of use, and consistent physico-chemical properties between batches. Its acceptance by BP, EP, and USP standards signals years of safe, verified usage and reassurance that raw material suppliers follow strict documentation and quality rules.
Polyoxyethylene (8) Stearate for pharmaceutical use falls under HS Code 34021300, which covers non-ionic organic surface-active agents. General specification sheets from trusted suppliers highlight purity minimums exceeding 98%, acid value limits below 2 mg KOH/g, saponification value between 95–115 mg KOH/g, and water content capped at 1%. These details confirm that each shipment matches high safety demands and will not introduce variable results downstream. Particle size and bulk density matter when high-throughput processes fill or blend powders, so certificates of analysis usually list routines for batch checks before acceptance into the warehouse. Because the product can absorb moisture from the air, staff must seal containers tightly after use and store them in cool, dry conditions away from reactive reagents and direct sunlight. Its low volatility helps keep dust and airborne particles to a minimum, reducing inhalation hazards in manufacturing settings.
End users, especially pharmacists and production technicians, rightly worry about ingredient safety. Polyoxyethylene (8) Stearate holds a solid reputation here. Acute toxicity tests show very low risk, with large margin of safety based on LD50 values in animal models. International standards from BP, EP, and USP include detailed toxicological reviews that back continued use in pharmaceuticals meant for vulnerable patient groups. Skin and eye irritation reports rarely turn up during standard patch testing, and the surfactant lacks the persistent environmental toxicity that causes stricter controls for other chemicals. Even so, handling recommendations advise wearing gloves and masks in case of dust formation, along with goggles if splashing could occur during solution preparation. Here, chemical stability stands out: The molecule shows little decomposition at pharmaceutical processing temperatures and holds up well in presence of mild acids or bases.
Most factories and compounding pharmacies order Polyoxyethylene (8) Stearate as large bags of flakes or pearls. These solid formats resist caking better and pour straightforwardly into mixing vessels. For specialty processing, such as direct compression tablets or rapid dissolution capsules, I’ve seen procurement teams opt for micronized powder, prized for its rapid hydration. On occasion, manufacturers sell it as an aqueous or ethanol-based concentrate, which saves time during high-speed blending or automated dosing in suspension production. Each format brings slight adjustments in density, flowability, and ease of weighing, but the chemistry remains the same in every batch. The choice comes down to the needs of the process—whether it runs at room temperature, whether hydration speed matters, or whether certain equipment handles solids or liquids more efficiently.
The thumbprint of Polyoxyethylene (8) Stearate shows up most obviously in emulsions and solutions. In my own work, I’ve prepared dozens of cream bases where oil and aqueous phases separate unless the right surfactant steps in. At roughly 1% to 3% w/w, this particular stearate stabilizes blends for months, guarding against creaming, breaking, or sedimentation. Nutraceutical drinks and flavored oral suspensions turn cloudy or phase-separate without ingredients like this behind the scenes. Unlike ionic surfactants, Polyoxyethylene (8) Stearate faces less risk of interacting with drug molecules or preservatives, so teams rarely need to alter formulas just to accommodate this raw material.
Even a reliable excipient brings some obstacles. I’ve heard quality assurance teams note potential for trace impurities if suppliers cut corners with feedstock purity or rush the ethoxylation reaction. Sometimes, overuse in a formula results in a heavy or greasy mouthfeel, especially in oral suspensions or gels. In highly sensitive injection formulations, presence of peroxides or residual catalysts calls for added purification steps and more rigorous verification testing. Manufacturers continue to monitor for trade-offs: stability comes from the eight oxyethylene groups, but too high a number might drag down water-insoluble drug solubility, or result in regulatory discomfort over PEG-related impurities. Solutions include rigorous supplier audits, routine lot testing, and clear documentation trails to align with pharmacopoeial and GMP requirements.
In the current regulatory climate, clean-label and “green” chemistry movements push companies to evaluate every excipient, even legacy ones like Polyoxyethylene (8) Stearate. Although this compound boasts a solid safety record, pressure mounts for renewable sourcing of stearic acid and minimization of process waste during ethoxylation. Pharmaceutical developers have experimented with alternative surfactants, but few match this stearate’s blend of low cost, consistent behavior, and global regulatory familiarity. Shifting toward fully traceable supply chains, with real-time certificates of analysis and digital batch tracking, lifts trust and reinforces the track record of Polyoxyethylene (8) Stearate in global pharma manufacturing.
Chengguan District, Lanzhou, Gansu, China
